## Org-12962

Cat. No.:	HY-118152		
CAS No.:	132834-56-1		
Molecular Formula:	C <sub>10</sub> H <sub>11</sub> ClF <sub>3</sub> N <sub>3</sub>		
Molecular Weight:	265.66		
Target:	5-HT Recep	tor	
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

## SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	3.7642 mL	18.8210 mL	37.6421 mL	
		5 mM	0.7528 mL	3.7642 mL	7.5284 mL	
		10 mM	0.3764 mL	1.8821 mL	3.7642 mL	
	Please refer to the solubility information to select the appropriate solvent.					
n Vivo		t one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline mg/mL (8.17 mM); Clear solution				
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.17 mg/mL (8.17 mM); Clear solution				
		one by one: 10% DMSO >> 90% cor ng/mL (8.17 mM); Clear solution	n oil			

BIOLOGICAL ACTIV	VITY		
Description	0 1 ,	15-HT <sub>2B</sub> receptor with pEC <sub>50</sub> s of $0$	tor agonist with a pEC <sub>50</sub> value of 7.01. Org-12962 also exhibits 6.38 and 6.28, respectively <sup>[1][3]</sup> .Org-12962 displays
IC₅₀ & Target	5-HT <sub>2C</sub> Receptor 7.01 (pEC50)	5-HT <sub>2A</sub> Receptor 6.38 (pEC50)	5-HT <sub>2B</sub> Receptor 6.28 (pEC50)

F ∣∠F

CI

Ν

ΗN

F

interruptio 0.9%) <sup>[1]</sup> . MCE has no Animal Moo Dosage:	interruption (F <sub>3.71</sub> =11.4 0.9%) <sup>[1]</sup> .	<ul> <li>Org-12962 (intraperitoneal injection; 0.3-3.2 mg/kg) significantly increases the postinjection frequency thresholds for self-interruption (F<sub>3.71</sub>=11.40). Org-12962 is dissolved or microsuspended in 0.3% v/v Tween 80 in physiological saline (NaCl 0.9%)<sup>[1]</sup>.</li> <li>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</li> </ul>	
	Animal Model:	Male Wistar rats <sup>[2]</sup>	
	Dosage:	0.3 mg/kg, 1 mg/kg, 3.2 mg/kg	
	Administration:	Intraperitoneal injection; 0.3-3.2 mg/kg	
	Result:	Induced a dose-related antipanic-like effect.	

## REFERENCES

[1]. Porter RH,et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.Br J Pharmacol. 1999 Sep;128(1):13-20.

[2]. Jenck F, et al. Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol. 1998 Aug;8(3):161-8.

[3]. Faassen F, et al. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.

Caution: Product has not been fully validated for medical applications. For research use only.